Samuel M. McCann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Samuel M. McCann has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- V. Rettori
Centro de Estudios Farmacológicos y Botánicos (CONICET), Serrano 669, Ciudad de Buenos Aires (1414), Argentina
4 shared publications Valeria Rettori
Centro de Estudios Farmocógicos y Botánicos, Consejo Nacional de Investigaciones Científicas y Técnicas, Serrano 669, 1414 Buenos Aires, Argentina
4 shared publicationsStefan R. Bornstein
Department of Medicine, Carl Gustav Carus University Medical School, and
2 shared publicationsA. Kamat
1 shared publicationAdriana del Rey
Department of Immunophysiology, Institute of Physiology, Medical Faculty, Philipps University, 35037 Marburg, Germany
1 shared publicationAida Baban
Molecular Cardioprotection and Inflammation Group, Department of Anesthesia
1 shared publication
Latest Publications
- Open Access
- 24 April 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (17) , 7205-7210
Caspase 1 deficiency reduces inflammation-induced brain transcription
The systemic inflammatory response syndrome (SIRS) is a life-threatening medical condition characterized by a severe and generalized inflammatory state that can lead to multiple organ failure and shock. The CNS regulates many features of SIRS such as fever, cardiovascular, and neuroendocrine responses. Central and systemic manifestations of SIRS can be induced by LPS or IL-1β administration. The crucial role of IL-1β in inflammation has been further highlighted by studies of mice lacking caspase 1 (casp1, also known as IL-1β convertase), a protease that cleaves pro-IL-1β into mature IL-1β. Indeed, casp1 knockout (casp1−/−) mice survive lethal doses of LPS. The key role of IL-1β in sickness behavior and itsde novoexpression in the CNS during inflammation led us to test the hypothesis that IL-1β plays a major role modulating the brain transcriptome during SIRS. We show a gene–environment effect caused by LPS administration in casp1−/−mice. During SIRS, the expression of several genes, such as chemokines, GTPases, the metalloprotease ADAMTS1, IL-1RA, the inducible nitric oxide synthase, and cyclooxygenase-2, was differentially increased in casp1−/−mice. Our findings may contribute to the understanding of the molecular changes that take place within the CNS during sepsis and SIRS and the development of new therapies for these serious conditions. Our results indicate that those genes may also play a role in several neuropsychiatric conditions in which inflammation has been implicated and indicate that casp1 might be a potential therapeutic target for such disorders.
- 24 April 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (17) , 7205-7210
Open AccessCaspase 1 deficiency reduces inflammation-induced brain transcription
The systemic inflammatory response syndrome (SIRS) is a life-threatening medical condition characterized by a severe and generalized inflammatory state that can lead to multiple organ failure and shock. The CNS regulates many features of SIRS such as fever, cardiovascular, and neuroendocrine responses. Central and systemic manifestations of SIRS can be induced by LPS or IL-1β administration. The crucial role of IL-1β in inflammation has been further highlighted by studies of mice lacking caspase 1 (casp1, also known as IL-1β convertase), a protease that cleaves pro-IL-1β into mature IL-1β. Indeed, casp1 knockout (casp1−/−) mice survive lethal doses of LPS. The key role of IL-1β in sickness behavior and itsde novoexpression in the CNS during inflammation led us to test the hypothesis that IL-1β plays a major role modulating the brain transcriptome during SIRS. We show a gene–environment effect caused by LPS administration in casp1−/−mice. During SIRS, the expression of several genes, such as chemokines, GTPases, the metalloprotease ADAMTS1, IL-1RA, the inducible nitric oxide synthase, and cyclooxygenase-2, was differentially increased in casp1−/−mice. Our findings may contribute to the understanding of the molecular changes that take place within the CNS during sepsis and SIRS and the development of new therapies for these serious conditions. Our results indicate that those genes may also play a role in several neuropsychiatric conditions in which inflammation has been implicated and indicate that casp1 might be a potential therapeutic target for such disorders.
- Open Access
- 6 February 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (6) , 2007-2012
Age-dependent regulation of chromaffin cell proliferation by growth factors, dehydroepiandrosterone (DHEA), and DHEA sulfate
The adrenal gland comprises two endocrine tissues of distinct origin, the catecholamine-producing medulla and the steroid-producing cortex. The inner adrenocortical zone, which is in direct contact with the adrenomedullary chromaffin cells, produces dehydroepiandrostendione (DHEA) and DHEA sulfate (DHEAS). These two androgens exhibit potential effects on neurogenesis, neuronal survival, and neuronal stem cell proliferation. Unlike the closely related sympathetic neurons, chromaffin cells are able to proliferate throughout life. The aim of this study was to investigate the effect of DHEA and DHEAS on proliferation of bovine chromaffin cells from young and adult animals. We demonstrated that graded concentrations of leukemia inhibitory factor induced proliferation of chromaffin cells from young animals, whereas EGF had no effect. On the contrary, EGF increased the cell proliferation in cells from adult animals, whereas leukemia inhibitory factor was inactive. In both cases, DHEA decreased the proliferative effect induced by the growth factors. Surprisingly, DHEAS enhanced, in a dose-dependent-manner, the effect of growth factors on proliferation in cells from adult animals but not from young animals. Flutamide, ICI 182,780, and RU 486 had no effect on the action of DHEA or DHEAS on chromaffin cell proliferation. These data show that DHEA and its sulfated form, DHEAS, differentially regulate growth-factor-induced proliferation of bovine chromaffin cells. In addition, the sensitivity of chromaffin cells to different growth factors is age-dependent. Furthermore, these two androgens may act through a receptor other than the classical steroid receptors.
- 6 February 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (6) , 2007-2012
Open AccessAge-dependent regulation of chromaffin cell proliferation by growth factors, dehydroepiandrosterone (DHEA), and DHEA sulfate
The adrenal gland comprises two endocrine tissues of distinct origin, the catecholamine-producing medulla and the steroid-producing cortex. The inner adrenocortical zone, which is in direct contact with the adrenomedullary chromaffin cells, produces dehydroepiandrostendione (DHEA) and DHEA sulfate (DHEAS). These two androgens exhibit potential effects on neurogenesis, neuronal survival, and neuronal stem cell proliferation. Unlike the closely related sympathetic neurons, chromaffin cells are able to proliferate throughout life. The aim of this study was to investigate the effect of DHEA and DHEAS on proliferation of bovine chromaffin cells from young and adult animals. We demonstrated that graded concentrations of leukemia inhibitory factor induced proliferation of chromaffin cells from young animals, whereas EGF had no effect. On the contrary, EGF increased the cell proliferation in cells from adult animals, whereas leukemia inhibitory factor was inactive. In both cases, DHEA decreased the proliferative effect induced by the growth factors. Surprisingly, DHEAS enhanced, in a dose-dependent-manner, the effect of growth factors on proliferation in cells from adult animals but not from young animals. Flutamide, ICI 182,780, and RU 486 had no effect on the action of DHEA or DHEAS on chromaffin cell proliferation. These data show that DHEA and its sulfated form, DHEAS, differentially regulate growth-factor-induced proliferation of bovine chromaffin cells. In addition, the sensitivity of chromaffin cells to different growth factors is age-dependent. Furthermore, these two androgens may act through a receptor other than the classical steroid receptors.
- 1 November 2006
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1088 (1) , 1-11
Chronology of Advances in Neuroendocrine Immunomodulationa
Abstract: This review documents the remarkable progress over the last 50 years of our knowledge of the control of anterior pituitary hormone release and synthesis by a family of peptidic releasing and inhibiting hormones, synthesized in hypothalamic neurons and released into the hypophysial portal vessels. These vessels transport them to the anterior pituitary, where they stimulate release and synthesis of pituitary hormones or inhibit these processes. In general, there are at least two hypothalamic hormones for each pituitary hormone–vasopressin and corticotrophin‐releasing hormone (CRH) for adrenocorticotropin hormone (ACTH) and growth hormone–releasing hormone (GHRH) and growth hormone–inhibiting hormone (GIH) for growth hormone (GH). Some of these hormones have extrapituitary action: for example, luteinizing hormone–releasing hormone (LHRH) stimulates mating behavior. High doses of LHRH have an inhibitory action on the growth of prostate cancer. Proinflammatory and anti‐inflammatory cytokines act not only in the brain, but also on the pituitary and peripheral tissues. All of these transmitters are controlled by neuronal transmitters. We anticipate further rapid progress and clinical application of these transmitters and the discovery of new ones.
- 1 November 2006
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1088 (1) , 1-11
Chronology of Advances in Neuroendocrine Immunomodulationa
Abstract: This review documents the remarkable progress over the last 50 years of our knowledge of the control of anterior pituitary hormone release and synthesis by a family of peptidic releasing and inhibiting hormones, synthesized in hypothalamic neurons and released into the hypophysial portal vessels. These vessels transport them to the anterior pituitary, where they stimulate release and synthesis of pituitary hormones or inhibit these processes. In general, there are at least two hypothalamic hormones for each pituitary hormone–vasopressin and corticotrophin‐releasing hormone (CRH) for adrenocorticotropin hormone (ACTH) and growth hormone–releasing hormone (GHRH) and growth hormone–inhibiting hormone (GIH) for growth hormone (GH). Some of these hormones have extrapituitary action: for example, luteinizing hormone–releasing hormone (LHRH) stimulates mating behavior. High doses of LHRH have an inhibitory action on the growth of prostate cancer. Proinflammatory and anti‐inflammatory cytokines act not only in the brain, but also on the pituitary and peripheral tissues. All of these transmitters are controlled by neuronal transmitters. We anticipate further rapid progress and clinical application of these transmitters and the discovery of new ones.
- 24 October 2006
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (43) , 16039-16044
IL-1 resets glucose homeostasis at central levels
Administration of IL-1beta results in a profound and long-lasting hypoglycemia. Here, we show that this effect can be elicited by endogenous IL-1 and is related to not only the capacity of the cytokine to increase glucose uptake in peripheral tissues but also to mechanisms integrated in the brain. We show that (i) blockade of IL-1 receptors in the brain partially counteracted IL-1-induced hypoglycemia; (ii) peripheral administration or induction of IL-1 production resulted in IL-1beta gene expression in the hypothalamus of normal and insulin-resistant, leptin receptor-deficient, diabetic db/db mice; (iii) IL-1-treated normal and db/db mice challenged with glucose did not return to their initial glucose levels but remained hypoglycemic for several hours. This effect was largely antagonized by blockade of IL-1 receptors in the brain; and (iv) when animals with an advanced Type II diabetes were treated with IL-1 and challenged with glucose, they died in hypoglycemia. However, when IL-1 receptors in the brains of these diabetic mice were blocked, they survived, and glucose blood levels approached those that these mice had before IL-1 administration. The prolonged hypoglycemic effect of IL-1 is insulin-independent and develops against increased levels of glucocorticoids, catecholamines, and glucagon. These findings, together with the present demonstration that this effect is integrated in the brain and is paralleled by IL-1beta expression in the hypothalamus, indicate that this cytokine can reset glucose homeostasis at central levels. Such reset, along with the peripheral actions of the cytokine, would favor glucose uptake by immune cells during inflammatory/immune processes.
- 24 October 2006
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (43) , 16039-16044
IL-1 resets glucose homeostasis at central levels
Administration of IL-1beta results in a profound and long-lasting hypoglycemia. Here, we show that this effect can be elicited by endogenous IL-1 and is related to not only the capacity of the cytokine to increase glucose uptake in peripheral tissues but also to mechanisms integrated in the brain. We show that (i) blockade of IL-1 receptors in the brain partially counteracted IL-1-induced hypoglycemia; (ii) peripheral administration or induction of IL-1 production resulted in IL-1beta gene expression in the hypothalamus of normal and insulin-resistant, leptin receptor-deficient, diabetic db/db mice; (iii) IL-1-treated normal and db/db mice challenged with glucose did not return to their initial glucose levels but remained hypoglycemic for several hours. This effect was largely antagonized by blockade of IL-1 receptors in the brain; and (iv) when animals with an advanced Type II diabetes were treated with IL-1 and challenged with glucose, they died in hypoglycemia. However, when IL-1 receptors in the brains of these diabetic mice were blocked, they survived, and glucose blood levels approached those that these mice had before IL-1 administration. The prolonged hypoglycemic effect of IL-1 is insulin-independent and develops against increased levels of glucocorticoids, catecholamines, and glucagon. These findings, together with the present demonstration that this effect is integrated in the brain and is paralleled by IL-1beta expression in the hypothalamus, indicate that this cytokine can reset glucose homeostasis at central levels. Such reset, along with the peripheral actions of the cytokine, would favor glucose uptake by immune cells during inflammatory/immune processes.
- Open Access
- 18 April 2006
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (16) , 6392-6397
Toll-like receptor 4 plays a crucial role in the immune–adrenal response to systemic inflammatory response syndrome
Sepsis and septic shock are leading killers in the noncoronary intensive care unit, and they remain worldwide health concerns. The initial host defense against bacterial infections involves Toll-like receptors (TLRs), which detect and respond to microbial ligands. In addition, a coordinated response of the adrenal and immune systems is crucial for survival during severe inflammation. Previously, we demonstrated a link between the innate immune system and the endocrine stress response involving TLR-2. Like TLR-2, TLR-4 is also expressed in human and mouse adrenals. In the present work, by using a low dose of LPS to mimic systemic inflammatory response syndrome, we have revealed marked cellular alterations in adrenocortical tissue and an impaired adrenal corticosterone response in TLR-4−/−mice. Our findings demonstrate that TLR-4 is a key mediator in the crosstalks between the innate immune system and the endocrine stress response. Furthermore, TLR polymorphisms could contribute to the underlying mechanisms of impaired adrenal stress response in patients with bacterial sepsis.
- 18 April 2006
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (16) , 6392-6397
Open AccessToll-like receptor 4 plays a crucial role in the immune–adrenal response to systemic inflammatory response syndrome
Sepsis and septic shock are leading killers in the noncoronary intensive care unit, and they remain worldwide health concerns. The initial host defense against bacterial infections involves Toll-like receptors (TLRs), which detect and respond to microbial ligands. In addition, a coordinated response of the adrenal and immune systems is crucial for survival during severe inflammation. Previously, we demonstrated a link between the innate immune system and the endocrine stress response involving TLR-2. Like TLR-2, TLR-4 is also expressed in human and mouse adrenals. In the present work, by using a low dose of LPS to mimic systemic inflammatory response syndrome, we have revealed marked cellular alterations in adrenocortical tissue and an impaired adrenal corticosterone response in TLR-4−/−mice. Our findings demonstrate that TLR-4 is a key mediator in the crosstalks between the innate immune system and the endocrine stress response. Furthermore, TLR polymorphisms could contribute to the underlying mechanisms of impaired adrenal stress response in patients with bacterial sepsis.
- 1 December 1996
- p. 105-12
The role of nitric oxide (NO) in control of hypothalamic-pituitary function.
Neurons containing neural nitric oxide synthase (nNOS) are found in various locations in the hypothalamus and, in particular, in the paraventricular and supraoptic nuclei with axons which project to the median eminence and extend into the neural lobe where the highest concentrations of NOS are found in the rat. Furthermore, nNOS is also located in folliculostellate cells and LH gonadotropes in the anterior pituitary gland. To define the role of NO in the release of hypothalamic peptides and pituitary hormones, we injected an inhibitor of NOS, Ng-monomethyl-L-arginine (NMMA) or a releasor of NO, nitroprusside (NP) into the third ventricle (3V) of conscious castrate rats and determined the effect on the release of various pituitary hormones. In vitro, we incubated medial basal hypothalamic (MBH) fragments and studied inhibitors of NO synthase and also releasors of NO. The results indicate that NOergic neurons play an important role in stimulating the release of corticotrophin-releasing hormone (CRH), luteinizing hormone releasing-hormone (LHRH), prolactin-RH's, particularly oxytocin, growth hormone-RH (GHRH) and somatostatin, but not FSH-releasing factor from the hypothalamus. NO stimulates the release of LHRH, which induces sexual behavior, and causes release of LH from the pituitary gland. The intrahypothalamic pathway by which NO controls LHRH release is as follows: glutamergic neurons synapse with noradrenergic terminals in the MBH which release nonepinephrine (NE) that acts on alpha 1 receptors on the NOergic neuron to increase intracellular free Ca++ which combines with calmodulin to activate NOS. The NOS diffuses to the LHRH terminal and activates guanylate cyclase (GC), cyclooxygenase and lipoxygenase causing release of LHRH via release of cyclic GMP, PGE2 and leukotrienes, respectively. Alcohol and cytokines can block LHRH release by blocking the activation of cyclooxygenase and lipoxygenase without interfering with the activation of GC. GABA also blocks the response of the LHRH neurons to NO and recent experiments indicate that granulocyte macrophage colony-stimulating factor (GMCSF) blocks the response of the LHRH neuron to NP by activation of GABA neurons since the blockade can be reversed by the competitive inhibitor of GABAa receptors, bicuculine.
- 1 December 1996
- p. 105-12
The role of nitric oxide (NO) in control of hypothalamic-pituitary function.
Neurons containing neural nitric oxide synthase (nNOS) are found in various locations in the hypothalamus and, in particular, in the paraventricular and supraoptic nuclei with axons which project to the median eminence and extend into the neural lobe where the highest concentrations of NOS are found in the rat. Furthermore, nNOS is also located in folliculostellate cells and LH gonadotropes in the anterior pituitary gland. To define the role of NO in the release of hypothalamic peptides and pituitary hormones, we injected an inhibitor of NOS, Ng-monomethyl-L-arginine (NMMA) or a releasor of NO, nitroprusside (NP) into the third ventricle (3V) of conscious castrate rats and determined the effect on the release of various pituitary hormones. In vitro, we incubated medial basal hypothalamic (MBH) fragments and studied inhibitors of NO synthase and also releasors of NO. The results indicate that NOergic neurons play an important role in stimulating the release of corticotrophin-releasing hormone (CRH), luteinizing hormone releasing-hormone (LHRH), prolactin-RH's, particularly oxytocin, growth hormone-RH (GHRH) and somatostatin, but not FSH-releasing factor from the hypothalamus. NO stimulates the release of LHRH, which induces sexual behavior, and causes release of LH from the pituitary gland. The intrahypothalamic pathway by which NO controls LHRH release is as follows: glutamergic neurons synapse with noradrenergic terminals in the MBH which release nonepinephrine (NE) that acts on alpha 1 receptors on the NOergic neuron to increase intracellular free Ca++ which combines with calmodulin to activate NOS. The NOS diffuses to the LHRH terminal and activates guanylate cyclase (GC), cyclooxygenase and lipoxygenase causing release of LHRH via release of cyclic GMP, PGE2 and leukotrienes, respectively. Alcohol and cytokines can block LHRH release by blocking the activation of cyclooxygenase and lipoxygenase without interfering with the activation of GC. GABA also blocks the response of the LHRH neurons to NO and recent experiments indicate that granulocyte macrophage colony-stimulating factor (GMCSF) blocks the response of the LHRH neuron to NP by activation of GABA neurons since the blockade can be reversed by the competitive inhibitor of GABAa receptors, bicuculine.
- 1 December 1995
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 771 (1 Stress) , 386-395
Mechanism of Action of Cytokines to Induce the Pattern of Pituitary Hormone Secretion in Infection
- 1 December 1995
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 771 (1 Stress) , 386-395
Mechanism of Action of Cytokines to Induce the Pattern of Pituitary Hormone Secretion in Infection
- 1 January 1990
- Published by Springer Nature
- Vol. 274, 315-329
Role of Monokines in Control of Anterior Pituitary Hormone Release
It has been known as far back as 1936 from the pioneering work of Selye (1) that noxious stimuli of one type or another, activate the release of ACTH which in turn releases adrenal cortical steroids. These then bring about a series of reactions in the body which consist of thymic involution, decrease in size of lymph nodes, lymphopenia, and eosinopenia (1). The role of the nervous system in these phenomena was not established at that time; however, in the early ’50s it became apparent that hypothalamic lesions, particularly in the median eminence of the tuber cinereum would abolish the release of ACTH and adrenal steroids resulting from stress (2). Conversely, stimulation of the hypothalamus could evoke release of ACTH followed by release of adrenal steroids (3).
- 1 January 1990
- Published by Springer Nature
- Vol. 274, 315-329
Role of Monokines in Control of Anterior Pituitary Hormone Release
It has been known as far back as 1936 from the pioneering work of Selye (1) that noxious stimuli of one type or another, activate the release of ACTH which in turn releases adrenal cortical steroids. These then bring about a series of reactions in the body which consist of thymic involution, decrease in size of lymph nodes, lymphopenia, and eosinopenia (1). The role of the nervous system in these phenomena was not established at that time; however, in the early ’50s it became apparent that hypothalamic lesions, particularly in the median eminence of the tuber cinereum would abolish the release of ACTH and adrenal steroids resulting from stress (2). Conversely, stimulation of the hypothalamus could evoke release of ACTH followed by release of adrenal steroids (3).
- 1 January 1986
- Vol. 42, 173-89
Gamma amino butyric acid (GABA) controls anterior pituitary hormone secretion.
Intraventricular injection (3V) of GABA can lead to a dose-related increase in plasma LH in ovariectomized (OVX) and OVX, estrogen-primed animals. Since the effects were blocked by the GABA receptor antagonist, bicucculine (B), they appear to be specific. These alterations in plasma LH were accompanied by alterations in hypothalamic LHRH, dopamine (DA) and norepinephrine (NE) content which suggests roles for all three compounds in the genesis of the increase in plasma LH. Since the DA receptor blocker pimozide (P) failed to block the elevation in LH induced by GABA it appears that the effect of GABA on LH release is mediated by NE. Others have found that the GABA agonist, muscimol, can lower plasma LH under certain conditions. Consequently, it appears likely that there may be opposite actions of GABA on LHRH release depending on the site of action within the hypothalamus. Intravenous (iv) injection of B in OVX rats produced an initial fall in plasma LH followed by a prolonged rise which again suggests several sites of action of GABA on LH release. GABA had no effect on FSH release consistent with separate control of this hormone. 3V injection of various doses of GABA produced a dose-related lowering of plasma TSH in OVX rats which appeared to be mediated by the dopaminergic system since P abolished the TSH-lowering of GABA. Following iv injection of B in normal male rats, there was a dramatic decline in TSH suggesting that under these conditions GABA would have a stimulatory action. Similar results were seen in OVX rats. The results indicate an important stimulatory action of GABA on TSH release in both males and OVX females. Perhaps the discrepancy between the results with B and GABA can be explained again by multiple sites of action of GABA of opposite sign. 3V injection of GABA induced a dose-related stimulation of growth hormone (GH) secretion; however, more recent evidence from other laboratories suggests that under certain conditions GABA has an inhibitory role in GH secretion. Again, we speculate that GABA had dual sites of action of opposite sign to affect GH. In contrast to the effects of GABA on these pituitary hormones, it appears to have a direct inhibitory effect on prolactin (Prl) secretion via the lactotrophs. Both stimulatory and inhibitory actions of GABA have been found following its injection into the brain. Studies with iv B also support dual actions on Prl release.
- 1 January 1986
- Vol. 42, 173-89
Gamma amino butyric acid (GABA) controls anterior pituitary hormone secretion.
Intraventricular injection (3V) of GABA can lead to a dose-related increase in plasma LH in ovariectomized (OVX) and OVX, estrogen-primed animals. Since the effects were blocked by the GABA receptor antagonist, bicucculine (B), they appear to be specific. These alterations in plasma LH were accompanied by alterations in hypothalamic LHRH, dopamine (DA) and norepinephrine (NE) content which suggests roles for all three compounds in the genesis of the increase in plasma LH. Since the DA receptor blocker pimozide (P) failed to block the elevation in LH induced by GABA it appears that the effect of GABA on LH release is mediated by NE. Others have found that the GABA agonist, muscimol, can lower plasma LH under certain conditions. Consequently, it appears likely that there may be opposite actions of GABA on LHRH release depending on the site of action within the hypothalamus. Intravenous (iv) injection of B in OVX rats produced an initial fall in plasma LH followed by a prolonged rise which again suggests several sites of action of GABA on LH release. GABA had no effect on FSH release consistent with separate control of this hormone. 3V injection of various doses of GABA produced a dose-related lowering of plasma TSH in OVX rats which appeared to be mediated by the dopaminergic system since P abolished the TSH-lowering of GABA. Following iv injection of B in normal male rats, there was a dramatic decline in TSH suggesting that under these conditions GABA would have a stimulatory action. Similar results were seen in OVX rats. The results indicate an important stimulatory action of GABA on TSH release in both males and OVX females. Perhaps the discrepancy between the results with B and GABA can be explained again by multiple sites of action of GABA of opposite sign. 3V injection of GABA induced a dose-related stimulation of growth hormone (GH) secretion; however, more recent evidence from other laboratories suggests that under certain conditions GABA has an inhibitory role in GH secretion. Again, we speculate that GABA had dual sites of action of opposite sign to affect GH. In contrast to the effects of GABA on these pituitary hormones, it appears to have a direct inhibitory effect on prolactin (Prl) secretion via the lactotrophs. Both stimulatory and inhibitory actions of GABA have been found following its injection into the brain. Studies with iv B also support dual actions on Prl release.